Gburugburu ụwa ndu mmiri ndu a na-eji ahịa kpọrọ ihe USD 1.3 Ijeri in 2020. By 2031, it is estimated that it will reach USD 6.9 Ijeri. This represents a 20.8% annual growth rate from 2022 to 2031.
Ọchịchọ na-eto eto
Asia-Pacific is projected to experience significant growth over the 2022-2029 forecast period. This is due to rising government awareness programs, medical tourism, increasing research activities in Asia-Pacific, rising cancer cases, and the growing demand for quality healthcare.
Nweta ihe atụ nke akụkọ iji nweta nghọta zuru oke @ https://market.us/report/liquid-biopsy-market/request-sample/
The country section of this report provides information on market-influencing factors and changes in domestic regulations that will impact market trends. To forecast the market for particular countries, data points like the downstream and the upstream value chain analysis as well as technology trends and porter’s five force analysis are used. Forecast analysis of country data also considers the presence and limitations of global brands and the challenges they face due to the competition from domestic and local brands.
Ihe Ọkwọ ụgbọala
Over the forecast period, the main driving factors for the United States liquid biopsy market are the increase in patient preference and cancer patients.
Ihe na-egbochi
However, market growth is expected to be hindered by the high costs associated with research and development professionals, the limited infrastructure facilities, and the lower sensitivity of liquid biopsies. The low reimbursement rate and low penetration of technology in developing countries will also be affected the market growth.
This market report on liquid biopsy provides detailed information about the latest developments, trade regulations, import-export analyses, production analysis, and value chain optimization. It also analyses the impact of localized market players. For more information on the liquid biopsy market, please contact Data Bridge Market Research. We will provide you with an Analyst Brief.
Mmepe nso nso a
- Guardant Health, Inc. (US) introduced its Guardant360 response test, which detects changes in the circulating tumor DNA (ctDNA).
- F. Hoffmann-La Roche Ltd., Switzerland, received FDA approval in October 2020 for expanded claims to the Cobas EGFR Mutation Test v2 that can be used as a companion diagnosis (CDx) for a wider variety of therapies for non-small-cell lung carcinoma (NSCLC).
- Biocept, Inc. (US) reached an agreement with a California-based independent physician association (IPA) in March 2020 to provide Target Selector liquid biopsy testing services to doctors and patients within the network.
Ụlọ ọrụ igodo
- RainDanceTechnologies
- Biocartis
- Guardant Health
- MDxHealth
- Pathway Genomics
- NeoGenomics Laboraories
- Sysmex Inostics
- Cynvenio
- Sistemụ Sistemụ Silicon Menarin
- qiagen
- Adaptive Biotechnologies
- Biocept
- Angle plc
Akụkụ ahịa igodo
ụdị
- CTC
- ctDNA
- Exosomes
ngwa
- Blood Sample based
- Urine Sample based
- Bio Fluids based
Ọtụtụ mgbe Ẹbụp Ajụjụ
- What are the most recent trends in the liquid biopsy?
- What are the most critical areas for liquid biopsy?
- Who are the major players in the liquid biopsy?
- Who are the top end users for liquid biopsy products & related services?
- Which region is the most lucrative for liquid biopsies?
Akụkọ metụtara:
Global Breast Cancer Liquid Biopsy Market Ihe kpatara uto ụlọ ọrụ, ụdị na ngwa ndị na-egwu egwu na amụma nyocha mpaghara na 2031
Global Liquid Biopsy Products Market Nyocha mpaghara ụlọ ọrụ mpaghara 2022 site na ntinye ego mmepụta ihe na ire ahịa na ọnụego uto.
Global Lung Cancer Liquid Biopsy Market Nyocha 2022 Nha ụlọ ọrụ ndị na-egwu egwu na-ekekọrịta nyocha usoro na amụma uto ruo 2031
Global Breast Biopsy Device Market Site n'aka ndị nrụpụta mpaghara Ngwa ụdị ngwaahịa ngwaahịa na amụma ruo 2031
Banyere Market.us
Market.US (Kwadoro site na Prudour Private Limited) ọkachamara na nyocha na nyocha miri emi. Ụlọ ọrụ a na-egosipụta onwe ya dị ka onye na-eduzi ndụmọdụ na onye nyocha ahịa ahaziri iche na onye na-eweta akụkọ nyocha ahịa ahịa nke a na-akwanyere ùgwù nke ukwuu.
Nkọwa kọntaktị:
Otu mmepe azụmahịa zuru ụwa ọnụ - Market.us
Market.us (Kwuru site na Prudour Pvt. Ltd.)
Adreesị: 420 Lexington Avenue, Suite 300 New York City, NY 10170, United States
Ekwentị: +1 718 618 4351 (International), Ekwentị: +91 78878 22626 (Asia)
email: [email protected]
IHE Ị GA-Ewepụ na edemede a:
- (US) reached an agreement with a California-based independent physician association (IPA) in March 2020 to provide Target Selector liquid biopsy testing services to doctors and patients within the network.
- This company has been proving itself as a leading consulting and customized market researcher and a highly-respected syndicated market research report provider.
- Over the forecast period, the main driving factors for the United States liquid biopsy market are the increase in patient preference and cancer patients.
